Kaleido Stock Performance

KLDO -  USA Stock  

USD 2.10  0.06  2.78%

The company secures a Beta (Market Risk) of 0.9121, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Kaleido's beta means in this case. Kaleido Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Kaleido Biosciences is expected to follow. Even though it is essential to pay attention to Kaleido Biosciences price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Kaleido Biosciences exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Kaleido Biosciences has an expected return of -1.02%. Please be advised to verify Kaleido Biosciences semi variance, and the relationship between the treynor ratio and daily balance of power to decide if Kaleido Biosciences performance from the past will be repeated at some point in the near future.

Kaleido Stock Performance 

 
Refresh
Kaleido Performance
0 of 100
Over the last 90 days Kaleido Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in February 2022. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more

Kaleido Price Channel

Quick Ratio2.89
Fifty Two Week Low2.0500
Target High Price22.00
Fifty Two Week High20.5000
Target Low Price3.00

Kaleido Biosciences Relative Risk vs. Return Landscape

If you would invest  427.00  in Kaleido Biosciences on October 26, 2021 and sell it today you would lose (216.00)  from holding Kaleido Biosciences or give up 50.59% of portfolio value over 90 days. Kaleido Biosciences is currently does not generate positive expected returns and assumes 4.8148% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Kaleido, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Kaleido Biosciences is expected to under-perform the market. In addition to that, the company is 5.69 times more volatile than its market benchmark. It trades about -0.21 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.07 per unit of volatility.

Kaleido Biosciences Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Kaleido Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kaleido Biosciences, and traders can use it to determine the average amount a Kaleido Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2112

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsKLDO
Estimated Market Risk
 4.81
  actual daily
 
 41 %
of total potential
 
4141
Expected Return
 -1.02
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.21
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Kaleido Biosciences is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kaleido Biosciences by adding it to a well-diversified portfolio.

About Kaleido Biosciences Performance

To evaluate Kaleido Biosciences Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Kaleido Biosciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Kaleido Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Kaleido Biosciences stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Kaleido's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(1.03) (1.11) 
Return on Average Equity(2.08) (2.14) 
Return on Invested Capital(4.34) (4.68) 
Return on Sales(72.76) (78.50) 
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Things to note about Kaleido Biosciences

Checking the ongoing alerts about Kaleido Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kaleido Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Kaleido Biosciences Alerts

Equity Alerts and Improvement Suggestions

Kaleido Biosciences generated a negative expected return over the last 90 days
Kaleido Biosciences has high historical volatility and very poor performance
Kaleido Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 855 K. Net Loss for the year was (90.03 M) with loss before overhead, payroll, taxes, and interest of (54.99 M).
Kaleido Biosciences currently holds about 55.66 M in cash with (71.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Kaleido Biosciences has a frail financial position based on the latest SEC disclosures
Over 82.0% of the company shares are owned by institutional investors
Latest headline from www.marketscreener.com: Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohns and Colitis Congress - marketscreener.com
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.